19/08/2021
The Food and Drug Administration (FDA) has approved a traditional Chinese drug for the treatment of mild coronavirus disease 2019 (COVID-19), the Chinese Embassy and FDA chief said Wednesday.
FDA Director General Eric Domingo told GMA News Online that the drug Lian Hua Qing Wen, produced by traditional Chinese medicine manufacturer Shijiazhuang Yiling Pharmaceutical Co. Ltd., was approved for use in the Philippines last week.
“It was approved last Friday as traditional medicine. It may now be sold, prescribed, and used in the Philippines,” he said in a text message.
“Lianhua Qingwen Capsule is an approved COVID-19 treatment for mild and moderate cases in China,” the Chinese Embassy also said in a separate statement.
The embassy noted that the drug has been approved in Hong Kong, Macau, Brazil, Indonesia, Canada, Mozambique, Romania, Thailand, Ecuador, Singapore, and Laos.
“It is our sincere hope that its entrance into the Philippine market will contribute to the fight against the spread of COVID-19 in this country and help the patients with mild and moderate symptoms recover,” it said.
The embassy also reminded consumers to purchase and consume authentic traditional Chinese medicine only.
The Philippines has logged 143,749 COVID-19 cases as of Wednesday afternoon.
Out of the 72,348 active cases undergoing treatment or quarantine, 91.3 percent are mild, 7.3 percent are asymptomatic, 0.6 percent are severe, and 0.7 percent are in critical condition. -NB, GMA News
This article FDA approves China drug Lian Hua Qing Wen for mild COVID-19 was originally published in GMA News Online.
